Patents by Inventor Boyu Zhong

Boyu Zhong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10947206
    Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
    Type: Grant
    Filed: April 15, 2018
    Date of Patent: March 16, 2021
    Assignees: ImmuneSensor Therapeutics, Inc., The Board of Regents of the University of Texas System
    Inventors: Boyu Zhong, Lijun Sun, Heping Shi, Jing Li, Chuo Chen, Zhijian Chen
  • Publication number: 20200010501
    Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
    Type: Application
    Filed: June 11, 2019
    Publication date: January 9, 2020
    Applicants: ImmuneSensor Therapeutics, Inc., The Board of Regents of the University of Texas System
    Inventors: Boyu ZHONG, Heping SHI, Yuanwei DAI, Qi WEI, Chuo CHEN, Zhijian CHEN, Lijun SUN
  • Patent number: 10519188
    Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
    Type: Grant
    Filed: April 15, 2018
    Date of Patent: December 31, 2019
    Assignees: ImmuneSensor Therapeutics, Inc., The Board of Regents of the University of Texas System
    Inventors: Boyu Zhong, Lijun Sun, Heping Shi, Qi Wei, Yuanwei Dai, Chuo Chen, Zhijian Chen
  • Publication number: 20180230177
    Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
    Type: Application
    Filed: April 15, 2018
    Publication date: August 16, 2018
    Inventors: Boyu ZHONG, Lijun SUN, Heping SHI, Qi WEI, Yuanwei DAI, Chuo CHEN, Zhijian CHEN
  • Publication number: 20180230115
    Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
    Type: Application
    Filed: April 15, 2018
    Publication date: August 16, 2018
    Inventors: Boyu ZHONG, Lijun SUN, Heping SHI, Jing Li, Chuo CHEN, Zhijian CHEN
  • Patent number: 10023593
    Abstract: An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: July 17, 2018
    Assignee: Beijing Pearl Biotechnology Limited Liability Company
    Inventors: Jiaqiang Dong, Boyu Zhong, Hongbin Yuan, Chuan Shih, Shaosong Chu, Deyi Zhang, Ruihao Zhang
  • Publication number: 20170247392
    Abstract: An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.
    Type: Application
    Filed: May 29, 2015
    Publication date: August 31, 2017
    Inventors: Jiaqiang DONG, Boyu ZHONG, Hongbin YUAN, Chuan SHIH, Shaosong CHU, Deyi ZHANG, Ruihao ZHANG
  • Patent number: 9695175
    Abstract: Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: July 4, 2017
    Assignee: CB THERAPEUTICS INC.
    Inventors: Boyu Zhong, Chuan Shih, Hongbin Yuan, Feng Zhou
  • Patent number: 9359338
    Abstract: Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: June 7, 2016
    Assignee: CROWN BIOSCIENCE INC. (Taiwan)
    Inventors: Deyi Zhang, Ruihao Zhang, Boyu Zhong, Chuan Shih
  • Publication number: 20150218171
    Abstract: Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.
    Type: Application
    Filed: August 1, 2013
    Publication date: August 6, 2015
    Inventors: Boyu Zhong, Chuan Shih, Hongbin Yuan, Feng Zhou
  • Publication number: 20150197511
    Abstract: Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.
    Type: Application
    Filed: June 24, 2013
    Publication date: July 16, 2015
    Inventors: Deyi Zhang, Ruihao Zhang, Boyu Zhong, Chuan Shih
  • Patent number: 8030302
    Abstract: The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: October 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Zhipei Wu, Wei Jennifer Yang, Boyu Zhong
  • Patent number: 7767674
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: August 3, 2010
    Assignee: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Yong Wang, Boyu Zhong, Jesus Andres Blas, Alfonso De Dios, Beatriz Lopez De Uralde-Garmendia, Luisa Maria Martin Cabrejas
  • Patent number: 7666879
    Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: February 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander McLean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Mai Yip, Boyu Zhong
  • Publication number: 20100022529
    Abstract: The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.
    Type: Application
    Filed: July 15, 2009
    Publication date: January 28, 2010
    Inventors: Tiechao LI, Mark Andrew POBANZ, Chuan SHIH, Zhipei WU, Wei Jennifer YANG, Boyu ZHONG
  • Patent number: 7652015
    Abstract: The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: January 26, 2010
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jesus Andres Blas de Blas, Alfonso De Dios, Kevin John Hudziak, Tiechao Li, Beatriz López De Uralde-Garmendia, Mary Margaret Mader, Michael Ray Myers, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • Publication number: 20090227622
    Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
    Type: Application
    Filed: February 23, 2006
    Publication date: September 10, 2009
    Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander Mclean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Yip, Boyu Zhong
  • Patent number: 7582638
    Abstract: The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Alfonso De Dios, Cristina Garcia-Paredes, Beatriz López de Uralde Garmendia, Mary Margaret Mader, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • Publication number: 20080306068
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Application
    Filed: June 15, 2005
    Publication date: December 11, 2008
    Applicant: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Yong Wang, Boyu Zhong, Jesus Andres Blas, Alfonso De Dios, Beatriz Lopez De Uralde-Garmendia, Luisa Maria Martin Cabrejas
  • Patent number: RE43878
    Abstract: The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: December 25, 2012
    Assignee: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Zhipei Wu, Wei Jennifer Yang, Boyu Zhong